Dimensional Fund Advisors LP Has $555.58 Million Stake in CVS Health Corporation $CVS

Dimensional Fund Advisors LP reduced its stake in shares of CVS Health Corporation (NYSE:CVS) by 12.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,369,261 shares of the pharmacy operator’s stock after selling 1,064,002 shares during the period. Dimensional Fund Advisors LP’s holdings in CVS Health were worth $555,577,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of CVS Health in the second quarter worth approximately $1,358,698,000. Invesco Ltd. raised its holdings in CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock worth $1,623,270,000 after purchasing an additional 3,118,626 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of CVS Health by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in shares of CVS Health by 153.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator’s stock valued at $214,240,000 after purchasing an additional 1,878,217 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of CVS Health by 2,675.7% during the second quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator’s stock worth $77,033,000 after buying an additional 1,076,509 shares during the period. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Up 0.1%

NYSE CVS opened at $80.57 on Thursday. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $102.50 billion, a P/E ratio of 58.38, a PEG ratio of 0.84 and a beta of 0.49. The business has a fifty day simple moving average of $78.53 and a 200 day simple moving average of $77.50. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last posted its earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The business’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, analysts predict that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.3%. The ex-dividend date was Thursday, January 22nd. CVS Health’s payout ratio is presently 192.75%.

Wall Street Analyst Weigh In

CVS has been the topic of a number of research analyst reports. TD Cowen upped their price target on shares of CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Truist Financial set a $100.00 price objective on CVS Health in a research note on Wednesday, December 10th. Bank of America decreased their target price on CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research note on Tuesday, January 27th. Wolfe Research dropped their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, The Goldman Sachs Group increased their price target on CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Nineteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.77.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.